NCT06922045 is a Phase 3 clinical trial of STSP-0601 for Injection in Hemophilia, sponsored by Jiangsu BioJeTay Biotechnology Co., Ltd..

Who is sponsoring NCT06922045?

NCT06922045 is sponsored by Jiangsu BioJeTay Biotechnology Co., Ltd..

What drugs are being tested in NCT06922045?

Interventions in NCT06922045: STSP-0601 for Injection.

What condition does NCT06922045 study?

NCT06922045 studies Hemophilia.

Is NCT06922045 still recruiting?

NCT06922045 is currently recruiting now. Last updated 22 April 2026.

Last reviewed 2026-04-22 · How we verify

NCT06922045

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase III Clinical Study on the Efficacy and Safety of STSP-0601 for Injection in Patients With Hemophilia Associated With Inhibitors, With a Multicenter, Open Evaluation Approach

Recruiting now Phase 3 Last updated 22 April 2026

What this trial tests

Phase 3 trial testing STSP-0601 for Injection in Hemophilia in 40 participants. Currently enrolling.

Timeline

26 March 2025

Primary endpoint
1 September 2026

1 March 2027

Quick facts

Lead sponsor	Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	26 March 2025
Primary completion	1 September 2026
Estimated completion	1 March 2027
Sites	18 locations across China

Drugs / interventions tested

STSP-0601 for Injection — full drug profile →

Conditions studied

Hemophilia — all drugs for Hemophilia →

Sponsor

Jiangsu BioJeTay Biotechnology Co., Ltd. — full company profile →

Who can join

Adults 12 to 70, any sex, with Hemophilia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

12 hours effective hemostasis rate
Time frame: 12 hours after the first administration

Sponsor's own description

This study will assess the efficacy of multiple-dose of STSP-0601 for the treatment of bleeding episodes in hemophilia A or B patients with inhibitor

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A specific FX activator for bleeding treatment in hemophilia with inhibitors: multicenter, open-label, phase 1/2 trials.
Liu W, Zhou H, Huang R, Du X, et al · · 2026 · PMID 41637644 · DOI 10.1182/bloodadvances.2025019486

Verify or expand the search:

Other trials of STSP-0601 for Injection

Trials testing the same drug.

NCT06289166 — Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor · Phase 2 · completed
NCT05619926 — Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor · Phase 2 · completed
NCT05027230 — A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor · Phase 1, PHASE2 · completed
NCT04747964 — A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor · Phase 1 · completed

Other recruiting trials for Hemophilia

Currently open trials in the same condition.

NCT07579585 — Effects of Photobiomodulation in Hemophilia Patients. · NA · recruiting
NCT07406139 — PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） · Phase 4 · recruiting
NCT07285460 — A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Year · Phase 3 · recruiting
NCT07187661 — Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis · NA · recruiting
NCT07099313 — Association of Prophylactic Treatment With Treatment Burden and Psychosocial Variables in Patients With Hemophilia · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06922045 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu BioJeTay Biotechnology Co., Ltd.
Last refreshed: 22 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06922045.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing